Buy Kombiglyze XR

Kombiglyze XR

Introduction: What Is Kombiglyze XR?

Kombiglyze XR is a prescription medication used in the United Kingdom to improve blood-glucose control in adults with type 2 diabetes. It combines two active ingredients-saxagliptin (a dipeptidyl-peptidase-4 inhibitor) and metformin (a biguanide). The product is available as an extended-release (XR) pill in two fixed-dose strengths: 5 mg/500 mg and 5 mg/1000 mg. Kombiglyze XR is classified as a prescription-only medicine (POM) and is marketed in the UK under the brand name Kombiglyze XR, produced by Merck Sharp & Dohme.

The medication is part of the broader therapeutic category of antidiabetic agents and is indicated as an adjunct to diet and exercise when metformin alone does not achieve glycaemic targets.

How Kombiglyze XR Works in the Body

Kombiglyze XR delivers two complementary mechanisms that together lower blood glucose:

• Saxagliptin blocks the enzyme dipeptidyl-peptidase-4 (DPP-4). DPP-4 normally degrades the incretin hormones GLP-1 and GIP, which stimulate insulin release after meals and suppress glucagon secretion. By inhibiting DPP-4, saxagliptin prolongs the action of these incretins, enhancing insulin secretion in a glucose-dependent manner and reducing hepatic glucose output.

• Metformin primarily reduces hepatic gluconeogenesis (the production of glucose by the liver). It also improves peripheral insulin sensitivity and modestly decreases intestinal absorption of glucose. Metformin’s effect does not rely on insulin secretion, making it useful across a wide range of patients with type 2 diabetes.

The extended-release formulation allows both agents to be absorbed gradually, providing once-daily dosing and smoother plasma concentration profiles. Onset of glucose-lowering action generally occurs within a few days, with the full therapeutic effect evident after several weeks of consistent use.

Conditions Treated by Kombiglyze XR

Kombiglyze XR is approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of type 2 diabetes mellitus in adults, when:

• Metformin monotherapy does not achieve target glycated haemoglobin (HbA1c) levels, and
• Additional glycaemic control is required without initiating insulin therapy.

The medication is intended for patients who are already on a stable dose of metformin and require an extra glucose-lowering agent. It is not approved for type 1 diabetes, gestational diabetes, or pediatric patients.

Patient Suitability and Contra-Indications

Who Should Use Kombiglyze XR?

• Adults (≥ 18 years) with type 2 diabetes who are already taking metformin.
• Individuals who require additional glucose-lowering efficacy and have no contraindications to saxagliptin or metformin.
• Patients with adequate renal function (estimated glomerular filtration rate, eGFR ≥ 45 mL/min/1.73 m²) for the standard doses.

Absolute Contra-Indications

• Known hypersensitivity to saxagliptin, metformin, or any inactive tablet ingredients.
• Severe renal impairment (eGFR < 30 mL/min/1.73 m²) or end-stage renal disease requiring dialysis.
• Hepatic disease associated with impaired drug metabolism (elevated liver enzymes > 3 × ULN).
• History of lactic acidosis or conditions that predispose to it (e.g., chronic alcohol abuse, severe infection, acute myocardial infarction).
• Prior pancreatitis related to DPP-4 inhibitor therapy.

Relative Contra-Indications & Special Populations

• Intermediate renal impairment (eGFR 30-44 mL/min/1.73 m²): dose reduction and close monitoring are advised.
• Elderly patients: start at the lower 5 mg/500 mg dose and assess tolerability.
• Pregnancy & lactation: saxagliptin is not recommended; metformin may be used when benefits outweigh risks, but Kombiglyze XR is generally avoided. Consultation with a specialist is essential.
• Patients on contrast imaging: metformin should be temporarily discontinued before and after iodinated contrast procedures to reduce the risk of lactic acidosis.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Gastro-intestinal (nausea, diarrhoea, abdominal discomfort) - often related to the metformin component.
• Upper respiratory symptoms (nasopharyngitis, cough).
• Headache and mild fatigue.

These events are usually mild, transient, and improve with continued therapy or dose adjustment.

Serious Adverse Events

• Lactic acidosis - a rare but potentially fatal metabolic complication associated with metformin, characterized by rapid breathing, muscle pain, and abdominal discomfort. Immediate medical attention is required.
• Pancreatitis - occasional reports of acute inflammation of the pancreas with saxagliptin. Presenting symptoms include severe abdominal pain radiating to the back, nausea, and vomiting.
• Severe hypersensitivity reactions - including rash, angioedema, or anaphylaxis.

Drug Interactions

• Renally cleared drugs (e.g., cimetidine, trimethoprim) may increase metformin concentrations; dose adjustments may be needed.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can raise saxagliptin levels, potentially heightening side-effect risk.
• Contrast media: Metformin should be withheld before and after iodinated contrast procedures in patients with reduced renal function.
• Alcohol: Excessive intake increases the risk of lactic acidosis; moderate consumption is advised.

Food and Lifestyle Interactions

• Take with meals: The XR tablet should be swallowed whole with a glass of water during or after a main meal to minimise gastrointestinal upset.
• Alcohol: Limit intake; avoid binge drinking.
• Driving: No specific impairment has been reported, but patients experiencing dizziness or severe gastrointestinal symptoms should exercise caution.

How to Take Kombiglyze XR

• Standard dosing: One tablet daily, either 5 mg/500 mg or 5 mg/1000 mg, taken with the first main meal of the day.
• Initiation: Therapy is typically started at the lower strength (5 mg/500 mg) to assess tolerability, then may be escalated to the higher dose if glycaemic targets are not reached.
• Renal adjustment: For eGFR 30-44 mL/min/1.73 m², the 5 mg/500 mg dose is recommended; avoid use if eGFR < 30 mL/min/1.73 m².
• Missed dose: Take the missed tablet as soon as you remember on the same day; do not double the next dose.
• Overdose: Symptoms may include severe gastrointestinal distress, lethargy, or breathing difficulties. Seek urgent medical care; supportive measures and, if needed, haemodialysis for metformin-related toxicity.
• Discontinuation: No taper is required, but abrupt cessation may lead to loss of glycaemic control. Continue monitoring blood glucose and follow up with your prescriber.

Monitoring and Follow-Up

• Renal function: Serum creatinine and eGFR at baseline, then at least annually; more frequently if renal function is borderline.
• Liver enzymes: Baseline assessment; repeat if clinical signs of hepatic dysfunction appear.
• HbA1c: Measured every 3 months after initiation or dosage change to evaluate efficacy.
• Blood glucose: Self-monitoring as advised by the diabetes care team.
• Adverse events: Report any signs of lactic acidosis, pancreatitis, or severe allergic reactions promptly.

Storage and Handling

• Store tablets at room temperature (15-25 °C), away from moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use tablets after the printed expiration date; discard any damaged or discoloured tablets.
• For safe disposal, follow local NHS guidelines or return unused medication to a pharmacy waste program.

Medication-Specific Glossary

DPP-4 Inhibitor

A class of drugs that block the enzyme dipeptidyl-peptidase-4, prolonging the activity of incretin hormones that stimulate insulin release.

Extended-Release (XR)

A formulation designed to release the active ingredients slowly over time, allowing once-daily dosing.

eGFR (Estimated Glomerular Filtration Rate)

A calculated measurement of kidney function, expressed in mL/min/1.73 m², used to guide dosing of renally cleared drugs.

Lactic Acidosis

A rare, serious metabolic disturbance characterized by accumulation of lactate in the blood, potentially fatal if not treated promptly.

Medical Disclaimer

This article provides educational information about Kombiglyze XR and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.